GLP-1s Like Semaglutide: Less Thyroid Cancer Than Insulin
Among people with type 2 diabetes who received a GLP-1 receptor agonist, there was less correlation between this treatment and thyroid cancer than among people with type 2 diabetes treated with insulin.